Click a keyword to view all the abstracts on this site tagged with that keyword.
- interstitial lung disease and Musculoskeletal
- interstitial lung disease and mycophenolate mofetil
- Interstitial lung disease and myopathy
- interstitial lung disease and myositis
- interstitial lung disease and outcome measures
- interstitial lung disease and polymyositis
- interstitial lung disease and polymyositis/dermatomyositis (PM/DM)
- interstitial lung disease and population studies
- interstitial lung disease and prognostic factors
- interstitial lung disease and pulmonary complications
- interstitial lung disease and pulmonary fibrosis
- interstitial lung disease and rheumatoid arthritis
- interstitial lung disease and rheumatoid arthritis (RA)
- interstitial lung disease and rituximab
- interstitial lung disease and scleroderma
- interstitial lung disease and serologic tests
- interstitial lung disease and Sjogren's syndrome
- interstitial lung disease and SSc-ILD
- interstitial lung disease and synthetase syndrome
- interstitial lung disease and systematic review
- interstitial lung disease and systemic lupus erythematosus (SLE)
- interstitial lung disease and systemic sclerosis
- Interstitial lung disease and tofacitinib
- interstitial lung disease and treatment
- interstitial lung disease and ulcers
- interstitial lung disease and ultrasound
- interstitial lung disease and vascular damage
- interstitial lung disease and vasculitis
- Intervention
- Intervention and Musculoskeletal
- Intervention and physical activity
- Intestinal flora
- intima medial thickness
- intima medial thickness and large vessel vasculitis
- intima medial thickness and meta-analysis
- intima medial thickness and rheumatoid arthritis (RA)
- intima medial thickness and systemic lupus erythematosus (SLE)
- intima medial thickness and tumor necrosis factor (TNF)
- intima medial thickness and vasculitis
- intra-articular corticosteroids
- Intracellular trafficking
- Intravenous Golimumab
- Intravenous immunoglobulin (IVIG)
- intravenous immunoglobulin (IVIG) and juvenile dermatomyositis
- intravenous immunoglobulin (IVIG) and parvovirus B19
- intravenous immunoglobulin (IVIG) and rituximab
- Intravenous immunoglobulin (IVIG) and scleroderma-like conditions
- intravenous immunoglobulin (IVIG) and small fiber neuropathy
- intravenous immunoglobulin (IVIG) and systemic lupus erythematosus (SLE)
- intravenous immunoglobulin (IVIG) and vasculitis
- intravenous infliximab
- intravenous methylprednisolone
- investigator
- IP-10
- IPAF
- Ipilimumab
- IPS (induced pluripotent stem cells)
- iPS (induced pluripotent stem cells) and osteoarthritis
- iPS (induced pluripotent stem cells) and tissue engineering
- irae
- IRF7 and glucocorticoids
- ITK
- Ixekizumab
- JAK
- Jak inhibitor
- JAK inhibitors
- JAK3
- Janus kinase
- Janus kinase (JAK)
- Janus kinase (JAK) and collagen
- Janus kinase (JAK) and disease-modifying antirheumatic drugs
- Janus kinase (JAK) and drug interactions
- Janus kinase (JAK) and Gene Expression
- Janus kinase (JAK) and interferons
- Janus kinase (JAK) and patient-reported outcome measures
- Janus kinase (JAK) and pharmacokinetics
- Janus kinase (JAK) and pharmacology
- Janus kinase (JAK) and psoriatic arthritis
- Janus kinase (JAK) and registry
- Janus kinase (JAK) and rheumatoid arthritis
- Janus kinase (JAK) and rheumatoid arthritis (RA)
- Janus kinase (JAK) and safety
- Janus kinase (JAK) and tofacitinib
- Janus kinase (JAK) and transcriptional regulation
- Janus kinase (JAK) and treatment
- Janus kinase (JAK) and tumor necrosis factor (TNF)
- Janus Kinase inhibitors
- japan and safety
- Japanese
- Japanese and human leukocyte antigens (HLA)
- Japanese and pharmacokinetics
- Japanese and rheumatoid arthritis (RA)
- Japanese and ulcers
- JDM
- JIA
- job loss and juvenile idiopathic arthritis (JIA)
- Joint
- Joint arthroplasty
- joint arthroplasty and osteoarthritis
- Joint arthroplasty and pain
- joint arthroplasty and prosthesis
- joint arthroplasty and risk
- joint arthroplasty and sex bias
- joint contractures
- joint damage
- joint damage and Disease Activity
- joint damage and modified stoke ankylosing spondylitis spinal score (MSASSS)
- joint damage and MRI
- joint damage and osteoarthritis
- joint damage and pain
- joint damage and pathogenesis
- joint damage and psoriatic arthritis
- joint damage and radiography
- joint damage and radiology
- joint damage and rheumatoid arthritis (RA)
- joint damage and signal transduction
- joint damage and spine involvement
- joint damage and synthetase syndrome
- joint damage and x-ray
- joint destruction
- joint destruction and autophagy proteins
- joint destruction and Disease Activity
- joint destruction and juvenile idiopathic arthritis (JIA)
- Joint destruction and matrix metalloproteinase (MMP)
- joint destruction and mitochondria
- joint destruction and osteoarthritis
- joint destruction and osteoclastogenesis
- joint destruction and osteoclasts
- Joint destruction and polymorphism
- joint destruction and progression
- joint destruction and radiography
- joint destruction and randomized trials
- joint destruction and rheumatoid arthritis
- Joint destruction and rheumatoid arthritis (RA)
- Joint effusion
- joint inflammation
- joint pain
- Joint procedures
- joint procedures and joint
- joint procedures and juvenile idiopathic arthritis (JIA)
- joint procedures and osteoarthritis
- joint procedures and rheumatoid arthritis (RA)
- joint procedures and safety
- joint procedures and ultrasound
- joint procedures and utilization review
- joint protection
- Joint replacement
- Joint Structure
- Journal
- jsle
- juvenile
- juvenile and whole-body
- Juvenile Arthritis
- juvenile arthritis and accommodation
- juvenile arthritis and cohort
- juvenile arthritis and juvenile idiopathic arthritis (JIA)
- juvenile arthritis and longitudinal studies
- juvenile arthritis and magnetic resonance imaging (MRI)
- juvenile arthritis and methotrexate (MTX)
- Juvenile arthritis and microbiome
- Juvenile arthritis and morbidity and mortality
- juvenile arthritis and musculoskeletal disorders
- juvenile arthritis and pain
- juvenile arthritis and pediatric rheumatology
- juvenile arthritis and polymorphism
- Juvenile arthritis and psoriatic arthritis
- juvenile arthritis and radiography
- juvenile arthritis and radiology
- juvenile arthritis and registry
- juvenile arthritis and spondylarthritis
- juvenile arthritis and synovial cells
- juvenile arthritis and synovitis
- juvenile arthritis and systemic lupus erythematosus (SLE)
- juvenile arthritis and therapeutic targeting
- juvenile arthritis and tocilizumab
- juvenile arthritis and tracking
- Juvenile arthritis and treatment
- Juvenile arthritis and uveitis
- juvenile arthritis and vaccines
- juvenile arthritis and young adults
- Juvenile Dermatomyosis
- juvenile dermatomyositis
- juvenile dermatomyositis and anti-mitochondria antibody
- juvenile dermatomyositis and genomics
- juvenile dermatomyositis and juvenile idiopathic arthritis (JIA)
- juvenile dermatomyositis and juvenile myositis
- juvenile dermatomyositis and lipids
- Juvenile dermatomyositis and magnetic resonance imaging (MRI)
- juvenile dermatomyositis and microparticles
- juvenile dermatomyositis and mitochondria
- Juvenile dermatomyositis and myositis
- juvenile dermatomyositis and nailfold capillaroscopy
- Juvenile dermatomyositis and natural killer (NK) cells
- juvenile dermatomyositis and neutrophils
- juvenile dermatomyositis and outcome measures
- juvenile dermatomyositis and outcomes
- juvenile dermatomyositis and pathogenesis
- juvenile dermatomyositis and pediatric rheumatology
- juvenile dermatomyositis and pediatrics
- juvenile dermatomyositis and polymyositis/dermatomyositis (PM/DM)